Virtual reality and scents could replace opioids for surgery pain
NCT ID NCT04912531
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining virtual reality with pleasant smells can lower pain and anxiety in people recovering from heart or lung surgery. About 80 adults scheduled for cardiothoracic surgery will either receive the VR-and-scent therapy or standard care. The goal is to see if this drug-free approach is practical and effective, potentially reducing the need for opioids.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2022
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Be scheduled to undergo any one of the 5 major types of cardiothoracic surgical operations: coronary artery bypass grafting, aortic valve replacement, aortic valve repair, lung resection, and esophagectomy * Age \> 18 * No cognitive or psychiatric conditions prohibiting study consent or participation. Exclusion Criteria: * Clinical signs of cardiogenic shock at time of surgery * Severe irreversible hypertension * Congenital heart disease * Chronic renal insufficiency defined by Cr ≥ 2.5 or chronic renal replacement therapy * Evidence of cirrhosis or hepatic synthetic failure * Patients with odor allergies or anosmia (lost their sense of smell)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anxiety postoperative are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Opioid-Free anesthesia in functional endoscopic sinus surgery: effects on perioperative outcomes - a prospective observational ERAS study
- A phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and dose expansion study of the peptide drug conjugate (PDC), TS-104, as a monotherapy in subjects with advanced solid tumors
- A dose-escalation, dose-extension and efficacy-extension, phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of AP-L1898 capsule for the treatment of the patients with locally advanced or metastatic non-small cell lung cancer
- PCI registry basel
- Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide
- Transgluteal versus transperineal pudendal nerve block for analgesia after hemorrhoidectomy: a randomized superiority trial (The PINPOINT trial)